Sona Asset Management US LLC Buys 200,000 Shares of Drugs Made In America Acquisition II Corp. $DMII

Sona Asset Management US LLC increased its position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) by 66.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the company’s stock after buying an additional 200,000 shares during the period. Sona Asset Management US LLC’s holdings in Drugs Made In America Acquisition II were worth $4,985,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. Virtu Financial LLC acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $317,000. ABC Arbitrage SA bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $396,000. Deltec Asset Management LLC acquired a new position in shares of Drugs Made In America Acquisition II during the fourth quarter worth approximately $495,000. Finally, Royal Bank of Canada bought a new position in shares of Drugs Made In America Acquisition II in the 4th quarter worth $655,000.

Wall Street Analyst Weigh In

Several analysts recently issued reports on DMII shares. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

Shares of DMII opened at $10.10 on Monday. Drugs Made In America Acquisition II Corp. has a 52 week low of $9.86 and a 52 week high of $10.11. The business’s 50 day moving average is $10.08.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.